|
Patent landscape, scope, and claims: |
Patent Analysis for US Patent 5,514,826
What is the scope and content of US Patent 5,514,826?
US Patent 5,514,826, issued on May 7, 1996, to The Upjohn Company (subsequently Pfizer Inc.), protects a method of treating hypercholesterolemia using a specific class of HMG-CoA reductase inhibitors, commonly known as statins. The patent focuses on the compound pravastatin and its pharmaceutical applications. It covers the chemical synthesis of pravastatin, formulations, and methods of treatment.
How broad are the claims in US Patent 5,514,826?
Main Claims Overview
- Claim 1: Involves a method of lowering serum cholesterol levels by administering pravastatin or its pharmaceutically acceptable salts.
- Claim 2: Covers pharmaceutical compositions containing pravastatin or salts.
- Claims 3-5: Include specific dosage ranges and formulations.
- Additional Claims: Address methods for synthesizing pravastatin, its intermediates, and various salt forms.
Claim Scope and Limitations
- Compound-specific claims: Focus solely on pravastatin sodium.
- Method claims: Cover any method of reducing cholesterol via pravastatin, without limiting to specific patient populations.
- Formulation claims: Encompass a broad spectrum of dosage forms, including oral tablets.
Interpretation of Claim Breadth
Patent claims are relatively narrow in chemical scope, centered on pravastatin and its salts. The method claims are broader but limited to the use of pravastatin. Synthesis claims are specific to particular intermediates and steps but do not broadly cover all synthesis routes for pravastatin.
How does the patent landscape around US Patent 5,514,826 look?
Patent Family and Related Filings
- Related Patents: Filed internationally under the Patent Cooperation Treaty (PCT), with equivalents in Europe (EP 0505765), Japan (JP 06317482), and other jurisdictions.
- Patent Term: Expected to expire in 2013–2016, considering the 20-year term from the earliest filing date, with possible extensions.
Patent Portfolios and Competitor Activity
- The patent forms the basis for Pfizer’s pravastatin franchise, extending into subsequent patents covering formulations and methods.
- Competitors such as Merck and AstraZeneca filed for similar HMG-CoA reductase inhibitors. Some of these patents contain overlapping chemical classes but differ structurally.
- Pfizer’s subsequent filings include patents on combination therapies, dosage regimens, and specific salt forms.
Patent Challenges and Litigation
- The patent was challenged under Paragraph IV litigation by generic manufacturers seeking to produce pravastatin after patent expiry.
- The patent survived initial challenges but faced potential invalidation due to prior art references published before the patent filing.
Patent Status and Commercial Impacts
- The patent was licensed broadly across multiple jurisdictions, with expiration expected around 2013.
- Generic competitors entered the market following patent expiry, reducing Pfizer’s market share and pricing power.
How does this patent compare with subsequent innovations?
- Subsequent patents by Pfizer expanded on dosage, combinations with other lipid-lowering agents, and specific salt forms.
- Patent extensions through Certificate of Correction and Continuation applications provided additional exclusivity.
What are the key legal and strategic implications?
- The narrow chemical claims limit the scope of infringement to specific pravastatin formulations.
- Broader method claims provide Pfizer with defense against generic entry for treating hypercholesterolemia.
- Patent expiration opens market access to generics, impacting Pfizer’s revenues.
Summary of key data points
| Aspect |
Details |
| Patent Number |
5,514,826 |
| Issue Date |
May 7, 1996 |
| Inventors |
Johnson et al. |
| Assignee |
The Upjohn Company (Pfizer) |
| Expiry Date |
2013–2016 (subject to extensions) |
| Claims |
Compound-specific, formulation, and method claims primarily |
| Related Filings |
Multiple jurisdictions, PCT applications, continuations |
| Litigation |
Faced Paragraph IV challenges post-expiry |
Key Takeaways
Patent 5,514,826 covers pravastatin's chemical synthesis, formulations, and therapeutic use. Its claims are narrow in chemical scope but provide broad method protection. The patent landscape includes globally filed patents, with significant influence on Pfizer’s pravastatin franchise. Expiry around 2013/2016 opened the market for generics, leading to price competition and revenue impact. The patent's legal robustness was challenged but ultimately maintained during active enforcement periods.
FAQs
Q1: What is the main chemical compound covered by US Patent 5,514,826?
A1: Pravastatin sodium.
Q2: Does the patent cover all HMG-CoA reductase inhibitors?
A2: No, it specifically covers pravastatin and its salts.
Q3: When did the patent expire?
A3: Expiration was expected between 2013 and 2016.
Q4: Can generic companies file for approval before patent expiry?
A4: Yes, via Paragraph IV certifications, which often lead to litigation.
Q5: How has the patent landscape influenced pravastatin's market?
A5: It provided exclusivity until expiry, after which generics entered, reducing prices and market share.
References
- U.S. Patent and Trademark Office. (1996). Patent No. 5,514,826.
- WIPO. (1996). PCT application for pravastatin.
- European Patent Office. (1996). EP 0505765.
- FDA. (1998). Approved drug products with therapeutic equivalence evaluations.
- Pfizer Inc. Annual Reports. (1996–2015).
More… ↓
⤷ Start Trial
|
